Istvan A Ember
Overview
Explore the profile of Istvan A Ember including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
57
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Faluhelyi Z, Rodler I, Csejtey A, Tyring S, Ember I, Arany I
Anticancer Res
. 2004 May;
24(2B):807-9.
PMID: 15161031
Earlier we found that SiHa cervical squamous carcinoma cells that harbor HPV type 16 respond to ATRA treatment in a dose-dependent manner: high-dose (10(-5)-10(-4) M) but not low-dose (10(-7)-10(-6) M)...
2.
Arany I, Chen S, Megyesi J, Adler-Storthz K, Chen Z, Rajaraman S, et al.
Cancer Lett
. 2003 Sep;
199(1):83-9.
PMID: 12963127
Overexpression of the epidermal growth factor receptor (EGFR) in the cancers of the head and neck is well demonstrated. In addition, copy numbers of the EGFR mRNA were significantly higher...
3.
Arany I, Grattendick K, Whitehead W, Ember I, Tyring S
Virology
. 2003 Jun;
310(2):280-6.
PMID: 12781715
We recently identified a new enhancer element (HIRE-1, HPV-Interferon Responsive Element-1) in the upstream regulatory region (URR) of human papillomavirus (HPV) type 16. HIRE-1 is located upstream from and in...
4.
Arany I, Whitehead W, Ember I, Tyring S
Anticancer Res
. 2003 Apr;
23(1A):495-7.
PMID: 12680256
SiHa cervical squamous carcinoma cells were resistant to ATRA-induced growth inhibitory effect at a physiological dose (10(-6) M), but responsive at a pharmacological dose (10(-4) M). The observed growth arrest...
5.
Arany I, Ember I, Tyring S
Anticancer Res
. 2003 Apr;
23(1A):471-3.
PMID: 12680251
Earlier we observed that all-trans-retinoic acid (ATRA) dose-dependently suppressed the growth of cervical carcinoma cells. Suppression of growth required sustained activation of interferon regulatory factor 1 (IRF-1), which was achieved...
6.
Arany I, Whitehead W, Grattendick K, Ember I, Tyring S
Clin Diagn Lab Immunol
. 2002 Sep;
9(5):1102-6.
PMID: 12204966
All-trans retinoic acid (ATRA) suppresses growth of cervical dysplasias in vivo, although the sensitivity to retinoids is frequently lost during cervical carcinogenesis. It has been suggested that prolonged treatment or...